Global Health
Global Health Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
4 of 5 strong
The short version
Cluster 2 hospitals excluding Noida show strong IPD volume growth of around 27%, with continued growth expected especially in Lucknow and Patna. Medanta expects continued robust growth driven by scaling of newer units like Noida, Lucknow, and Patna, which are strong growth engines.
From Global Health's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- Cluster 2 hospitals excluding Noida show strong IPD volume growth of around 27%, with continued growth expected especially in Lucknow and Patna.
- Lucknow and Patna are adding procedural capacity and bed capacity, supporting further volume increases.
- Cluster 1 hospitals (Gurgaon, Indore, Ranchi) exhibit steady double-digit volume growth despite large base.
- Additional bed capacity and procedural expansion planned in Indore and Ranchi to support growth and add missing services like cancer care.
- Noida facility expected to achieve operating leverage with scale-up, aiding margin improvement and revenue growth.
- Expansion in Guwahati with increased procedural capacity anticipates market capture in Northeast, broadening geographic reach and driving volume.
2 more points from Global Health's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Global Health said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Revised Guwahati hospital expansion to a 650-bed super specialty facility with an estimated project cost of INR 970 crore (~INR 9,700 million), up from earlier plans of 400 beds and INR 500 crore capex, driven by increased procedural capacity and expanded floor area under new building codes.
- Brownfield expansion underway in Cluster 1 hospitals: added 100 beds in Ranchi, acquired 80-bed facility in Indore expected to be operational by Q2/Q3; also activating additional operating rooms and cath labs in Gurgaon.
- Ongoing capex of INR 161 crore (INR 1,610 million) incurred in Q1 FY27; future capex requirement stands at INR 4,850 crore.
- Continued investment in advanced technology including LINAC equipment for cancer treatment, robotic procedure capabilities, and radiation oncology infrastructure.
2 more points from Global Health's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Global Health said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Global Health's call on order book
Pro opens every point from 15K+ earnings calls
Global Health — Quarterly revenue & net profit
Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹1.2K Cr, net profit ₹142 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Global Health Ltd's management said in earlier quarters
- Q4 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Healthcare Services this season
- Aatmaj Healthcare Ltd (Q1 FY27)
Revenue for Q1 FY 2026-27: ₹8.13 crore . Key investor presentation takeaways from Aatmaj Healthcare Ltd's Q1 FY27 investor presentation — and how it ranks again
- Asarfi Hospital (Q1 FY27)
Q1'FY27 consolidated revenue from operations: ₹47.5 Cr, up 32.8% YoY (vs ₹35.7 Cr in Q1'FY26) . Key investor presentation takeaways from Asarfi Hospital Ltd's Q
- 3B Blackbio (Q1 FY27)
Q1 2026-27 revenue from operations: ₹3,205.73 Lakh (including Coris sales of ₹862.83 Lakh) vs ₹1,996.06 Lakh in Q1 2025-26 — YoY growth approx. Key concall…
- Thyrocare Tech. (Q1 FY27)
Pathology business grew ~27%; franchisee business grew ~23-27% YoY, reflecting strong volume growth. Key concall takeaways from Thyrocare Technologies Ltd's Q1…
Arthneeti Pro · Annual
Global Health and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Global Health Q1 FY27 results?
Cluster 2 hospitals excluding Noida show strong IPD volume growth of around 27%, with continued growth expected especially in Lucknow and Patna. Medanta expects continued robust growth driven by scaling of newer units like Noida, Lucknow, and Patna, which are strong growth engines.
What is Global Health share price analysis?
Global Health currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 66.2 with a market cap of ₹37,903 Cr. Investors should review the full earnings analysis for detailed insights.
Is Global Health planning capital expenditure?
Revised Guwahati hospital expansion to a 650-bed super specialty facility with an estimated project cost of INR 970 crore (~INR 9,700 million), up from earlier plans of 400 beds and INR 500 crore capex, driven by increased procedural capacity and expanded floor area under new building codes.
Keep Global Health on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.